If it does pop up the method of treatment is usually based upon what trimester of pregnancy the woman is in. Those that are diagnosed during the first trimester are recommended to terminate the pregnancy because of the outcome chances. If they receive the anthracycline-containing regimens and keep the baby, there are chances of fetal death and malformation. If they still decide to keep the baby, they will still receive conventional chemotherapy and be closely watched. There are different options of treatment for those in their second or third trimester. Some evidence reports that it is possible to have a safe pregnancy while receiving chemotherapy at this time. There was a successful delivery for 73% out of 160 pregnant women diagnosed with different cancers and treated with anthracyclines. While there may be possibilities of a safe pregnancy during chemotherapy, there is also a long-term risk to the fetus. Pregnant women that are treated with chemotherapy for hematologic malignancies, have the highest rate of long-term risk of this chemotherapy exposure in
If it does pop up the method of treatment is usually based upon what trimester of pregnancy the woman is in. Those that are diagnosed during the first trimester are recommended to terminate the pregnancy because of the outcome chances. If they receive the anthracycline-containing regimens and keep the baby, there are chances of fetal death and malformation. If they still decide to keep the baby, they will still receive conventional chemotherapy and be closely watched. There are different options of treatment for those in their second or third trimester. Some evidence reports that it is possible to have a safe pregnancy while receiving chemotherapy at this time. There was a successful delivery for 73% out of 160 pregnant women diagnosed with different cancers and treated with anthracyclines. While there may be possibilities of a safe pregnancy during chemotherapy, there is also a long-term risk to the fetus. Pregnant women that are treated with chemotherapy for hematologic malignancies, have the highest rate of long-term risk of this chemotherapy exposure in